Filip Goossens

Filip Goossens is the current director at reMYND. Prior to that, they were a senior business and investment manager at Sopartec sa from July 2015 to July 2020. Sopartec is the Technology Transfer and investment company of the Université catholique de Louvain. Sopartec's mission, within the Louvain Technology Transfer Office, is to bring the results of research carried out by UCL, the Cliniques universitaires St-Luc and the Institute de Duve (ICP) by creating spin-offs and negotiating licence agreements.

Sopartec is also the management company of the Vives Louvain Technology Fund. Vives is a technology multi-sectorial fund that invests in UCL spin-offs and startups in both Belgium and neighboring countries.

Prior to working at Sopartec, Filip was an investment manager at Vives Louvain Technology Fund from July 2015 to July 2020. Vives is a private seed capital that invests in high-technology companies. This multi-sectoral fund supports young companies in all technological sectors. Vives invests in companies at all stages of maturity: seed, start-up and growth.

Within Vives, Filip focused on Health & Engineering. As Investment Manager, their aim was to aid young entrepreneurs in shaping their business plan with a focus on market challenges (commercial), and communication in the broadest sense (internal, external and financial).

Filip Goossens studied small business administration and management at the Solvay Brussels School of Economics and Management. Filip then pursued a career in clinical biology at the University of Antwerp. After obtaining their Ph.D. in pharmacology from the University of Antwerp, they received a CEIPI certificate from CEIPI Strasbourg.